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The distal splenorenal shunt (DSRS) was compared with the
side-to-side portacaval shunt (PCS) in 93 prospectively
matched patients with portal hypertension. After 38 months
mean follow-up the two shunts had a different incidence of
acute encephalopathy (22% in PCS group and 33% in DSRS
group) and chronic encephalopathy (35% in PCS group and
17% in DSRS group), but the difference was not statistically
significant. However, the only cases of severe and disabling
chronic encephalopathy arose after PCS (p = 0.049). Acuarial
curves of chronic encephalopathy showed that the maximum
rate of encephalopathy (18%) in the DSRS group was reached
27 months after shunt surgery, whereas this value was reached
and passed in PCS group only 4 months after shunt. Chronic
encephalopathy occurred for a total duration of 20.1 months
after PCS and only 11.1 months after DSRS (p = 0.003) and
occupied 46.3% of the follow-up ofPCS patients, as contrasted
to 18.7% of the follow-up of DSRS patients (p = 0.0001).
DSRS is associated with a lower global incidence of chronic
HE without severe forms and provides a better quality of life
than does a nonselective shunt.
P5 ORTAL-SYSTEMIC SHUNTS, removing portal hy-
pertension, represent the only definitive treat-
ment for the prevention of variceal rebleeding.'
However, suppression of hepatopetal flow could cause
the appearance of hepatic encephalopathy (HE) and
liver function deterioration.2
Distal splenorenal shunt (DSRS), first proposed by
Warren et al. in 19673 appeared to be an interesting
alternative in the treatment of bleeding esophageal var-
ices. The effectiveness of the selective shunt in control-
ling bleeding has been documented in several reports."
Moreover, a concomitant significant decrease of HE
after DSRS when compared to traditional nonselective
shunts was observed.7'2 The initial enthusiasm has been
cooled by recent results of clinical trials, which cast
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doubts on whether the selective shunt is truly superior in
preventing HE.'3-'6 In this study results on HE are pre-
sented, comparing DSRS with side-to-side portacaval
shunt (PCS), a classical nonselective anastomosis.
Materials and Methods
Between January 1980 and June 1984, 152 adult pa-
tients were submitted to portal-systemic shunt for portal
hypertension at the First Surgical Clinic of the Univer-
sity ofMilan. Ninety-three patients were selected for this
study on the basis of the following criteria: (1) biopsy-
documented cirrhosis; (2) at least one episode of upper
gastrointestinal bleeding caused by esophageal varices
and confirmed by endoscopy; (3) proof of hepatopetal
portal blood flow during the venous phase of the supe-
rior mesenteric angiography; (4) angiographical avail-
ability to perform both the shunts; (5) no severe ascites
at the time of operation; and (6) surgery on an elective
basis only. Patients older than 65 years of age or with
hepatic failure (Child's C patients) were also excluded.
Table 1 shows the reasons for the exclusion of 59 pa-
tients. Informed written consent was obtained from all
patients prior to their inclusion in the study. A group of
47 patients submitted to a PCS was matched by a group
of 46 patients who had received a DSRS. Patients were
matched for age, sex, number of preoperative bleeds,
type of cirrhosis, degree of portal perfusion, and preop-
erative functional hepatic reserve as determined by the
Child's classification and by a global score, already de-
scribed by the authors.6
Patients were submitted to one of the shunts accord-
ing to an alternative method ofassignment in the morn-
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TABLE 1. Reasonsfor the Exclusion ofthe Patientsfrom the Study
No. of Patients
Prophylactic shunts 12
Emergency shunts 15
Budd-Chiari syndrome 4
Other PCS 8
Central splenorenal shunts 13
Other shunts 6
Nonselected patient I
Total 59
ing before shunt surgery. However, when the selected
shunt was intraoperatively judged unsuitable for ana-
tomic reasons and the other shunt could be performed,
the patient still included in the study because all the
criteria for inclusion were met. This method was chosen
because randomization was not feasible in this depart-
ment.6 The sample requirements to demonstrate an in-
crease in survival at 5 years of the 10% are about 500
patients for each group, applying standard power (80%),
Type I error (p < 0.05), and a two-tailed t-test." This
would mean that a long recruitment period and/or mul-
ticenter study can be expected to provide meaningful
results. However, HE is the most important complica-
tion of shunt surgery. Therefore, the value of DSRS in
preventing HE was studied. The sample requirements to
demonstrate a decrease in HE from 40% to 15% are
about 46 patients for each group, applying standard
power (80%), Type I error (p < 0.05) and a two-tailed
t-test.'7 The choice of this method of assignment and
this specific objective has limited the recruitment period
to 54 months.
Preoperative Evaluation
History of cirrhosis was collected in each patient with
particular attention to previous episodes ofgastrointesti-
nal bleeding and evidence of either primary or post-
hemorrhagic hepatic failure (jaundice, ascites, or
TABLE 2. Preoperative Characteristics ofthe Two Study Groups
PCS DSRS
(N = 47) (N = 46) pValue
Age (mean) 50.2 ± 9.5 54.0 ± 7.0 0.05
Sex (M/F) 38/9 31/15 NS
Bleeding episodes from
esophageal varices (mean) 1.57 1.82 NS
Primitive hepatic falure
(none/one or more) 17/30 19/27 NS
Child's classification
A 0 0
B 46 46 NS
C 1 0
Portal perfusion
1 30% 35%
2 48% 42% NS
3 22% 23%.
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TABLE 3. Etiology ofLiver Cirrhosis
PCS DSRS
Posthepatitic 16 19
Alcoholic 23 18
Cryptogenetic 7 8
Other 1 I
edema) (Table 2). Physical examination was specifically
directed to the assessment of nutritional state, hepato-
splenomegaly, jaundice, ascites, and edema. Routine
laboratory tests were employed to evaluate the func-
tional state of the liver. An overall assessment of the
severity of liver disease was made. The mean index of
PCS cases (0.58 ± 0.08) was similar to that of DSRS
(0.60 ± 0.06; NS). Serum a-fetoprotein was routinely
determined in order to screen the presence of hepatic
neoplasm. The etiology of cirrhosis was determined on
the basis ofclinical history, serum markers ofviral hepa-
titis, and liver biopsy (Table 3). The presence of esopha-
geal varices was assessed by endoscopic examination.
Criteria used for classifying the endoscopic findings were
based on the General Rules for Recording Endoscopic
Findings on Esophageal Varices compiled by the Japa-
nese Research Society for Portal Hypertension.'8
Cerebral function was assessed by a complete neuro-
logic examination, taking into account the mental state,
asterixis, electroencephalographic findings (EEG) and
the trail making test.'9'20 All were assessed using the 0-4
rating system proposed by Conn.2' The Cancelling As
test was also used22 and rated by the same method. This
test assesses preattentive visual processing. The subject
is asked to cancel out words containing As from long list
of words in a specified time period. Each parameter was
arbitrarily weighed in proportion to its importance. An
overall score for HE was calculated from the sum of the
values for each of the five parameters (Table 4). HE was
considered acute if it was precipitated by gastrointestinal
bleeding, acute binge drinking, or pharmacologic or di-
etary imbalances, ofbriefduration and easily controlled
with elimination ofthe precipitating cause. HE was con-
TABLE 4. Assessment ofHE
Degree
0 1 2 3 4
Mental state 0 4 8 12 16
Asterixis 0 1 2 3 4
Cancelling A's test 0 0.5 1 1.5 2
TMT. 0 0.5 1 1.5 2
EEG. 0 1 2 3 4
No HE = 0-4.
Mild HE = 5-10.
Moderate HE = 11-20.
Severe HE = 20.
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sidered chronic if it was spontaneous, of long duration,
and more difficult to manage. Preoperative HE was ex-
cluded in all patients.
A visceral angiography was obtained by selective cath-
eterization of celiac axis and superior mesenteric artery.
The venous phase ofangiography showed patency ofthe
portal venous system and hepatopetal portal flow in all
patients. The degree of hepatic perfusion was evaluated
according to the criteria of Nordlinger et al."3
Operative Management
All patients were operated by the same surgical team
and in the same time period. Side-to-side PCS was per-
formed following standard technique. DSRS was con-
structed according to a previously described technique
(37 cases)3'4 or by a modification (nine cases).24 A com-
plete portal-azygous disconnection, with interruption of
the left gastric, right gastroepiploic, and pyloric veins
was always added.
Mesenteric venous pressure before and after the con-
struction of the anastomosis was intraoperatively re-
corded by direct catheterization of an ileal vein, the
plane of the caval vein was used as 0 baseline. Further-
more, direct measurement of splenic pressure was ob-
tained in all DSRS patients.
Postoperative Evaluation
After surgery all vital parameters were continuously
monitored and serial laboratory tests ofhepatic function
were obtained. An esophageal endoscopy was performed
in each patient. A visceral angiography was performed
on the tenth average postoperative day only in patients
submitted to DSRS. Shunt patency was directly verified
on the venous phase of angiography in the DSRS group
and indirectly by endoscopic variceal examination in
the PCS group. Three DSRS patients and one PCS pa-
tient were excluded from the analysis of the later results
because two patients died in the early postoperative pe-
riod (one for each group). One DSRS patient had shunt
thrombosis and one with Britton's operation had lack of
splenic ligation resulting in a side-to-side splenorenal
shunt. The former was given beta-blockade therapy.
Both patients were still alive without complications with
a follow-up of 36 and 42 months, respectively.
Patients were checked at the first, third, and sixth
month after discharge; follow-up was then extended to
at least twice yearly on an outpatient basis. At each visit
liver function was assessed by a complete clinical and
biologic examination. A longitudinal assessment ofliver
function was made by calculating an index based on a
battery of laboratory tests (albumin, total bilirubin,
prothrombin time, SGOT, alkaline phosphatase) using
the same method as for the assessment of the global
score of functional hepatic reserve.6 This index was ob
tained at 6 months and then yearly after surgery and
compared each time with preoperative values. The as-
sessment of neurologic status was performed using the
afore-mentioned criteria. An EEG was obtained at least
once a year. Any period of chronic HE in any month
was counted as 1 month in that functional category."
An assessment of quality of life was calculated by divid-
ing the number of months with chronic HE by the fol-
low-up of each patient, giving a percentage." Evidence
ofHE between two subsequent controls was determined
based on history of neuropsychiatric aberrations de-
scribed by the patients and/or reliable witnesses that
were not explained by stroke, intoxication, or other dis-
order. A return to drinking was based on patient's state-
ments, the authors' assessment, and informations from
relatives. Continued drinking was defined as daily con-
sumption in excess of 1 L of wine and/or hard liquors.
All the patients were on a protein-balanced diet (1 g
protein/kg body weight) and administered lactulose
prophylactic treatment; the dosage was started at 60
g/day in three divided doses and adjusted thereafter to
induce at least one bowel movements per day.
Data Management and Statistical Analysis
Initial evaluation and subsequent follow-up data were
collected on 1-2-3 databases (Lotus Development Corp.)
for computer input (Epson PC AX, Seiko Epson Corp.)
and subsequent analysis (Microstat Ecosoft, Inc., India-
napolis, IN). Cumulative curves of chronic HE were
analyzed by the Kaplan-Meier method and were com-
pared by the log-rank test.25 Comparison between
groups was made by the chi square test for proportions
and Mann-Whitney U-test for the means.
Results
Prior to inclusion in the study, acute HE had occurred
in eight ofthe 47 patients in the PCS group (17%) and in
ten ofthe 46 patients in the DSRS group (21 %) (NS). In
most patients HE was associated with gastrointestinal
bleeding, was transient, and cleared with minimal thera-
peutic steps including lactulose and sometimes amino
acid infusion. Postoperatively, acute HE occurred in
four of the 46 patients in the PCS group (9%) and in six
ofthe 43 patients in the DSRS group (14%) (NS). Long-
term follow-up was complete in 100% of patients. Mean
follow-up time from operation to last data analysis (both
alive and dead patients) was 39 months in the DSRS
group and 41 months in the PCS group (range: 24-79
months; NS). Acute HE was observed in ten of 46 pa-
tients in the PCS group (22%) compared to 14 of 43
patients in the DSRS group (33%) (NS). Chronic HE
was evaluated by its incidence, seriousness, onset, and
duration. Chronic HE was observed in 16 patients in the
PCS group (35%) and in seven patients in the DSRS
group (17%) (NS). Chronic HE was mild in eight PCS
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patients (17%), moderate in four (9%), and severe in four
others (9%). After DSRS no severe HE was found, but
five patients (12%) suffered a mild form and two (5%) a
moderate form. The difference in the incidence ofsevere
HE between PCS and DSRS groups was slightly signifi-
cant (p = 0.049). The cumulative curve of patients free
ofchronic HE (Fig. 1) showed that the maximum rate of
HE in DSRS group (18%) was reached 27 months after
shunt surgery, whereas this value was reached and
passed only 4 months after PCS. The 16 patients in the
PCS group experienced a mean of 20. 1 months (± 14.9)
with chronic HE, whereas the mean for the seven pa-
tients in the DSRS group was only 1 1.1 months (±8. 1)
(p = 0.003). These 16 PCS patients had 46.3% (±30%) of
their follow-up period with chronic HE, whereas the
seven DSRS patients had only 18.7% (±14.6%). This
difference is highly significant (p = 0.0001).
Figure 2 demonstrates the mean indices of liver func-
tion calculated for the two surgical groups during the
follow-up period. The DSRS did not cause any signifi-
cant worsening of hepatic function, whereas PCS did.
Discussion
The aim of this study was to compare the incidence of
HE after DSRS and PCS in two homogeneous groups of
cirrhotic patients, matched for clearly established crite-
ria of inclusion. The two groups of patients were homo-
geneous with regard to liver function, type of cirrhosis,
preoperative portal hemodynamics, and indications for
surgery. Some advantages of this study were that DSRS
was compared only with PCS as a nonselective shunt,
surgery was performed by the same team that had ac-
quired experience with 590 nonselective and 60 selective
shunts,' ensuring fairly good standardization of the sur-
gical approach, and serial follow-up checks were made
for virtually the same period for both groups. Finally, no
patient was lost during follow-up period.
Assessment ofHE and quantification of its symptoms
remain a much debated point with no immediate solu-
tion in sight.26 Severe forms are easy enough to identify,
but subclinical signs are easy to overlook on superficial
examination. We attempted to standardize our assess-
ment of these disturbances using a score of HE amply
inspired by the criteria set out by Conn et al.2' Using an
empirical rating scale, the absence of HE, and mild,
moderate, and severe forms were defined. A clear-cut
definition was used for acute and chronic HE because of
the widely differing impact of these two forms on social
life and habits. Isolated and recurrent episodes of acute
HE occurred more often after DSRS than PCS; this dif-
ference, however, was not statistically significant and
also not clinically relevant. Other studies showed that
acute HE, as it was induced by comagenic events, oc-
curred in equally large fractions of both shunted and
nonshunted patients.27-30 These data indicate that acute
patients free
of chronic HE
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FIG. 1. Actuarial curves of patients free of chronic HE.
HE is a common phenomenon in cirrhotic patients with
portal hypertension. On the other hand, chronic HE was
usually associated with portal-systemic shunts.27 Six
prospective studies compared DSRS and nonselective
shunts; results have shown a significantly lower fre-
quency ofHE following DSRS.7-'6
The results of the current study showed that the qual-
ity of life after DSRS is superior to that after PCS. This
finding is based on the different behavior of chronic HE
in the two groups regarding to incidence, seriousness,
onset, and duration. First, after a follow-up of at least 2
years only 17% of DSRS patients have experienced
chronic HE, as contrasted to 35% of PCS patients. This
difference, however, was not statistically significant, but
it seems to be clinically important. The size of the study
may have prevented the observation of a significant ef-
fect. Second, the only cases of severe and disabling
chronic HE arose after PCS, and this was slightly statis-
tically significant. One cause for severe forms of chronic
HE could be continued alcoholism. A direct relationship
between active drinking and spontaneous HE was seen
indices of
liver function
(366. 3c
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58
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FIG. 2. Longitudinal trend of indices of liver function in PCS group. *p
< 0.05 and +p < 0.02 compared to preoperative values.
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only in the DSRS group. 6 This suggests that the natural
history of chronic HE in this population depends on the
direct effect ofcontinued drinking, whereas the develop-
ment ofHE after PCS is hemodynamic above all.'6 Five
PCS patients (11%) and four DSRS patients (9%) had
returned to drinking. However, none of these patients
had severe HE and only one DSRS patient had a moder-
ate form. Moreover, we analyzed if the difference in the
incidence of severe form could be caused by a dietary
imbalance, constipation, and/or additional therapies.
HE in PCS group was not caused by other disorders.
Two PCS patients and four DSRS patients were on a
free diet, whereas five PCS patients had to interrupt the
protein intake to prevent the development of chronic
HE (NS). Lactulose prophylactic treatment was inter-
rupted in three PCS and in five DSRS patients of their
own free will (NS). Oral BCAA dietary supplementation
(Friliver, Bracco) was necessary in nine PCS patients
and in four DSRS patients (NS). Third, in those patients
in whom chronic HE developed after DSRS, it did so
later in their postoperative course. Chronic HE devel-
oped so soon after PCS that its incidence surpassed the
maximum incidence ofHE in DSRS group (18%) just 4
months after hospital discharge. Fourth, chronic HE
lasted longer after PCS than after DSRS. This influenced
the lifestyle of PCS patients including modifications of
their work performance or partial limitations of house-
hold ability. Some patients required assistance for the
basic activities of daily living. In contrast, HE caused 38
late admissions in 19 PCS patients but only 18 late ad-
missions in 11 DSRS patients. Thus, the risk of admis-
sion for HE was almost twofold higher in the PCS group
(0.83 vs. 0.42 admissions per patient; p = 0.037). Fur-
thermore, these admissions were caused by acute HE in
all but three PCS patients who were admitted for
chronic HE. The reasons for this better quality of life in
DSRS group are still discussed.
Chronic HE is related to three physiologic factors:
hepatic portal perfusion, portal-systemic collaterals,
and intestinal venous hypertension that affects intestinal
absorption.31,32 Altered portal hemodynamics impairs
liver function in cirrhotics, which may be responsible for
the development of chronic HE.30'33 However, much
controversy exists regarding HE following shunt sur-
gery, namely, whether it is due to the shunt itself or to
the hepatic damage.
Suppression of portal diversion led to complete rever-
sal of severe, disabling postshunt encephalopathy.34,35 It
has reported a low frequency ofHE in portal hyperten-
sion with good preservation of hepatic function such as
schistosomiasis36 or Budd-Chiari syndrome.37 In con-
trast, the incidence of HE in patients with an impaired
liver function (Child's C risk) submitted to endoscopic
sclerotherapy was similar to that of shunted patients.38
However, these can be considered borderline cases in
whom it is possible (at least theoretically) to separate the
altered portal hemodynamic effect from the impaired
liver function. In the majority of cases, this is very diffi-
cult. In this study the cumulative curve of patients free
of chronic HE (Fig. 1) after PCS seems to have two
components: a rapid initial slope for 12 months after
discharge followed by a more gentle slope thereafter,
whereas the curve after DSRS showed a more progres-
sive slope from beginning to end. The rapid develop-
ment of chronic HE after PCS could be due to the im-
provised loss of portal perfusion contributing to hepato-
cellular damage (Fig. 2). However, the progressive
development of chronic HE after DSRS could be due to
the evolutive chronic disease. It is known that loss of
liver volume occurs in unoperated patients and proba-
bly represents the natural history of disease.39
Portacaval shunt diverts portal venous flow away
from the liver, contributing to liver failure. Further-
more, a toxic substance or substances from the gastroin-
testinal tract bypass their normal metabolic site in the
liver and reach the brain in high concentrations, where
they produce cerebral dysfunction. Finally, total portal-
systemic shunt causes increased ammonia absorption
from the small and large bowel due to decompression of
the splanchnic circulation.
DSRS should represent optimal surgical therapy be-
cause postoperative portal perfusion and superior mes-
enteric-portal venous hypertension are maintained;
these aim to preserve liver cell function in the already
impaired liver of cirrhotics.12 However, six randomized
controlled trials have demonstrated conflicting results
regarding subsequent incidence of HE.9"' 1-14,16
The lack of a clearly positive effect on HE after DSRS
may be due to (besides afore-mentioned natural history
of liver disease) the progressive loss of shunt selectiv-
ity.40-43 In our experience of 1 8 DSRS performed, pre-
operative and postoperative splanchnic angiography
were evaluated in 80 cases. Patients with loss of portal
perfusion had higher incidence of chronic HE (25%)
than patients with other degrees of perfusion (6%, (p
= 0.02) (unpublished observation). The rate of loss of
perfusion may be accelerated by inadequate portal-azy-
gous disconnection."'45 High rates ofHE after modified
DSRS (without portal-azygous disconnection) seem to
confirm these data.46'47 Warren et al.48 projected that if
the splenic vein were completely separated from the
pancreas during selective shunt, (splenopancreatic dis-
connection) the so-called pancreatic siphon would not
develop and postoperative portal perfusion and shunt
selectivity could be preserved.
In conclusion, DSRS is associated with less global in-
cidence of chronic HE, absence of severe forms, less
rapid development during follow-up, and less duration
of episodes providing a better quality of life than does a
nonselective shunt.
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